Recently it was found that FGF21 serves as a potential negative regulator of PCSK9 (Guo et al. 2016), which is in line with our observation that hypermethylation of PCSK9 corresponds with higher circulating FGF21 levels in patients with hypercholesterolemia compared to control subjects. Here, PCSK9 is linked to familial hypercholesterolemia.